Skip to Content

Edarbi Approval History

FDA Approved: Yes (First approved February 25, 2011)
Brand name: Edarbi
Generic name: azilsartan medoxomil
Dosage form: Tablets
Company: Takeda Pharmaceutical Company Limited
Treatment for: High Blood Pressure

Edarbi (azilsartan medoxomil) is an angiotensin II receptor blocker (ARB) for the treatment of hypertension.

Development History and FDA Approval Process for Edarbi

DateArticle
Feb 28, 2011Approval FDA Approves Edarbi to Treat High Blood Pressure
Apr 27, 2010Takeda Submits New Drug Application for Azilsartan Medoxomil in the U.S., an Investigational Compound for the Treatment of Hypertension

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Hide